CRISPR Unlocks Sweeter Tomatoes Without Yield Loss
Carbon
Nov. 19, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
ART Bioscience
Company Type: Therapeutic development
Main focus: Advancing novel genetic therapies to treat genetic musculoskeletal system disorders
Company stage: Pre-clinical
Diseases: Duchenne muscular dystrophy and other genetic musculoskeletal system disorders
Genome-editing tool: CRISPR-Cas9
Funding stage: Unknown
Location: Rehevot, HaMerkaz, Israel
Website: https://www.artbioscience.com/
Pipeline: www.artbioscience.com/pipeline
Partners:
ART Bioscience is a pre-clinical stage biotechnology company focused on developing mRNA-based therapies for rare diseases, with a primary focus on duchenne muscular dystrophy (DMD). The company uses mRNA therapy and gene editing based on CRISPR-Cas9 technology to target genetic variants responsible for DMD. ART Bioscience aims to offer therapies based on protein replacement and gene editing to restore functional dystrophin protein in patients. The company’s pipeline consists of three investigational therapeutics for DMD involving mRNA therapy and gene-editing platforms.
